297 related articles for article (PubMed ID: 22037934)
21. FDG-PET/CT in lymphoma.
Juweid ME
Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925
[TBL] [Abstract][Full Text] [Related]
22. 18F-FDG PET and PET/CT in Burkitt's lymphoma.
Karantanis D; Durski JM; Lowe VJ; Nathan MA; Mullan BP; Georgiou E; Johnston PB; Wiseman GA
Eur J Radiol; 2010 Jul; 75(1):e68-73. PubMed ID: 19716248
[TBL] [Abstract][Full Text] [Related]
23. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
24. FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the posttherapy evaluation of malignant lymphoma.
Okada M; Sato N; Ishii K; Matsumura K; Hosono M; Murakami T
Radiographics; 2010; 30(4):939-57. PubMed ID: 20631361
[TBL] [Abstract][Full Text] [Related]
25. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
Hutchings M
Hematol Oncol Clin North Am; 2014 Feb; 28(1):87-103. PubMed ID: 24287070
[TBL] [Abstract][Full Text] [Related]
26. (18)F-FDG-PET/CT in evaluating response to therapy in solid tumors: where we are and where we can go.
Herrmann K; Benz MR; Krause BJ; Pomykala KL; Buck AK; Czernin J
Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):620-32. PubMed ID: 22231582
[TBL] [Abstract][Full Text] [Related]
27. Use of PET/CT to evaluate response to therapy in lymphoma.
Zanoni L; Cerci JJ; Fanti S
Q J Nucl Med Mol Imaging; 2011 Dec; 55(6):633-47. PubMed ID: 22231583
[TBL] [Abstract][Full Text] [Related]
28. [Significance of (18)F-FDG-PET/CT for staging and evaluation of therapeutic effect in patient with malignant lymphoma].
Li F; Zhu HY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):523-7. PubMed ID: 21518522
[TBL] [Abstract][Full Text] [Related]
29. Role of 2-Deoxy-2-[18F]-fluoro-d-glucose-PET/Computed Tomography in Lymphoma.
Tirumani SH; LaCasce AS; Jacene HA
PET Clin; 2015 Apr; 10(2):207-25. PubMed ID: 25829087
[TBL] [Abstract][Full Text] [Related]
30. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
31. [Imaging examinations in lymphoma].
Terauchi T
Nihon Rinsho; 2014 Mar; 72(3):430-5. PubMed ID: 24724398
[TBL] [Abstract][Full Text] [Related]
32. [Importance of PET/CT in lymphoma diagnostics].
Afshar-Oromieh A; Kratochwil C; Haberkorn U; Giesel FL
Radiologe; 2012 Apr; 52(4):338-46. PubMed ID: 22526115
[TBL] [Abstract][Full Text] [Related]
33. Staging and response assessment in lymphomas: the new Lugano classification.
Cheson BD
Chin Clin Oncol; 2015 Mar; 4(1):5. PubMed ID: 25841712
[TBL] [Abstract][Full Text] [Related]
34. [The role of PET imaging in patients with lymphoma].
Klaeser B; Krause T
Ther Umsch; 2010 Oct; 67(10):505-10. PubMed ID: 20886456
[TBL] [Abstract][Full Text] [Related]
35. Imaging of non-Hodgkin lymphomas: diagnosis and response-adapted strategies.
El-Galaly TC; Hutchings M
Cancer Treat Res; 2015; 165():125-46. PubMed ID: 25655608
[TBL] [Abstract][Full Text] [Related]
36. The impact of fluorodeoxyglucose-positron emission tomography in primary staging and patient management in lymphoma patients.
Allen-Auerbach M; de Vos S; Czernin J
Radiol Clin North Am; 2008 Mar; 46(2):199-211, vii. PubMed ID: 18619376
[TBL] [Abstract][Full Text] [Related]
37. PET/CT, MR, and PET/MR in Lymphoma and Melanoma.
Schwenzer NF; Pfannenberg AC
Semin Nucl Med; 2015 Jul; 45(4):322-31. PubMed ID: 26050659
[TBL] [Abstract][Full Text] [Related]
38. [F-18 fluorodeoxyglucose positron emission tomography in malignant lymphoma].
Mikosch P
Wien Med Wochenschr; 2002; 152(11-12):269-75. PubMed ID: 12138654
[TBL] [Abstract][Full Text] [Related]
39. PET imaging for response assessment in lymphoma: potential and limitations.
Schöder H; Moskowitz C
Radiol Clin North Am; 2008 Mar; 46(2):225-41, viii. PubMed ID: 18619378
[TBL] [Abstract][Full Text] [Related]
40. ¹⁸F-FDG PET and PET/CT patient preparation: a review of the literature.
Surasi DS; Bhambhvani P; Baldwin JA; Almodovar SE; O'Malley JP
J Nucl Med Technol; 2014 Mar; 42(1):5-13. PubMed ID: 24503347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
